Skip to main content
PDEX
NASDAQ Industrial Applications And Services

Pro-Dex Q1 Sales Up 11% to $20.6M, Gross Margin 33%; Net Income Falls on Prior-Year Investment Gain

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$61.6
Mkt Cap
$199.167M
52W Low
$28.578
52W High
$77
52W Position info
116% above low
Off High info
20% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

PDEX has more than doubled off its 52-week low of $28.578.

Summary

Pro-Dex opened fiscal 2027 with $20.6M in sales (up 11%) and 33% gross margin, but net income fell to $3.0M from $4.7M on a prior-year investment gain. Backlog stands at $43.1M, and three insiders adopted new 10b5-1 selling plans.


Key Events · Earnings and Guidance · PDEX

  • Q1 Sales Up 11% to $20.6M

    Net sales rose to $20,560 thousand from $18,530 thousand, led by medical device sales up 21% to $17.4M; repair revenue fell 44% to $2.1M.

  • Gross Margin Expands to 33%

    Gross profit rose 28% to $6,857 thousand from $5,367 thousand, with margin up four points to 33% on favorable product mix.

  • Net Income Falls to $3.0M

    Net income was $3,048 thousand ($0.95 basic, $0.92 diluted) versus $4,680 thousand ($1.43, $1.40), as the prior year included a $3,299 thousand unrealized investment gain.

  • Backlog $43.1M for Fiscal 2027

    Firm purchase orders totaled approximately $43.1 million at September 30, 2026, with $42.4 million scheduled for delivery during the remainder of fiscal 2027.


Analysis · PDEX · Industrial Applications And Services

Sales grew 11% and gross margin expanded four points to 33%, but net income dropped to $3.0M from $4.7M because last year's quarter included a $3.3M unrealized investment gain that did not repeat. Backlog of $43.1M, with $42.4M due this fiscal year, gives unusually strong revenue visibility for a company this size. The offsetting risks are concentration (one customer is 72% of sales) and a supplier delay that could push next-generation handpiece shipments behind schedule. Separately, three insiders — the chairman, a director, and the CEO — adopted 10b5-1 selling plans covering up to $5.0M, 150,000 shares, and 20,000 shares respectively, which adds a future supply overhang.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PDEX was trading at $61.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $199.2M. The 52-week trading range was $28.58 to $77.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PDEX - Latest Insights

PDEX
Oct 29, 2026, 4:00 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $61.25
Real-time Price: $65.60 info
Change: +$4.35 (+7%) info
Market Cap: $210.112M info
PDEX
Sep 03, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.00
Real-time Price: $65.60 info
Change: +$0.600 (+0.92%) info
Market Cap: $210.112M info
PDEX
Sep 03, 2026, 4:10 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $65.00
Real-time Price: $65.60 info
Change: +$0.600 (+0.92%) info
Market Cap: $210.112M info
PDEX
Sep 03, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $65.00
Real-time Price: $65.60 info
Change: +$0.600 (+0.92%) info
Market Cap: $210.112M info
PDEX
Jun 26, 2026, 5:59 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $61.47
Real-time Price: $65.60 info
Change: +$4.13 (+7%) info
Market Cap: $210.112M info